



Ind-Swift Laboratories Limited

(A Recognised Export House)

Regd. Office : S.C.O. 850, Shivalik Enclave, NAC, Manimajra, Chandigarh - 160 101
Phones : ++ 91 - 172-2730503, 2730920, Fax + + 91 - 172 - 2730504, 2736294
E-mail : info@indswiftlabs.com Website : www.indswiftlabs.com



Ref:ISLL:CH:2012:

30th May, 2012

TO: ALL THE STOCK EXCHANGES

SUB: DISCLOSURES PURSUANT TO CLAUSE 20, 22 and 41 OF THE LISTING AGREEMENT

Dear Sir,

This is to inform the Exchange that the Board of Directors of the Company in its meeting held today i.e. 30th May, 2012 have approved the following :-

1. The Board has considered and approved the Annual Audited Accounts for the year ended 31st March, 2012. A copy of the results and information as per clause 20 of the Listing Agreement is enclosed herewith.
2. The Board of Directors have decided to plough back the profit for this year for future corporate needs, so has not declared any dividend on Equity Shares of the Company.
3. The Board has allotted 10,000 equity shares to the Independent Directors of the Company under Employee Stock option Scheme, 2006, at a price of Rs.27/- per share.

You are requested to take the same on record.

Thanking you,

For IND-SWIFT LABORATORIES LTD.

(PARDEEP VERMA)
GM-CORPORATE AFFAIRS &
COMPANY SECRETARY

Encl.: As above



Ind-Swift

Ind-Swift LABORATORIES LIMITED

(A Recognised Export House)

Regd. Office : S.C.O. 850, Shivalik Enclave, NAC, Manimajra, Chandigarh - 160 101
 Phones : ++ 91 - 172-2730503, 2730920, Fax + + 91 - 172 - 2730504, 2736294
 E-mail : info@indswiftlabs.com Website : www.indswiftlabs.com



AUDITED FINANCIAL RESULTS FOR THE YEAR ENDED 31ST, MARCH 2012

Particulars	STANDALONE					(₹ In Lacs)	
	STANDALONE		STANDALONE		STANDALONE		CONSOLIDATED
	Quarter Ended 31.03.2012	Quarter Ended 31.12.2011	Quarter Ended 31.03.2011	Year ended 31.03.2012	Year ended 31.03.2011	Year ended 31.03.2012	Year ended 31.03.2011
	Audited	Unaudited	Audited	Audited	Audited	Audited	Audited
(a) Net Sales/Incomes from Operations	35861.53	35178.11	30341.34	132068.13	101972.54	140917.45	103704.35
Total Net Sales / Operating income	35861.53	35178.11	30341.34	132068.13	101972.54	140917.45	103704.35
Total Expenditure :	36069.30	35880.41	30714.75	133839.56	103014.21	142798.92	104746.02
a Cost of Materials Consumed	21356.47	23993.44	14359.14	72049.44	43385.24	80178.98	90231.63
b Purchase of stock in Trade	9997.44	8670.43	13865.42	40034.57	45653.33	40034.57	45653.33
c. (Increase) /decrease in stock in trade	(1064.04)	(5969.64)	(4361.03)	(8120.72)	(12950.10)	(8120.72)	(12950.10)
d. Staff cost	799.09	677.68	461.32	2715.46	1999.61	2869.28	1999.35
e. Depreciation	308.02	1132.64	1064.89	3986.09	3851.64	3986.09	3851.64
f. Impairment of Assets	(100.00)	20.00	41.35	0.00	241.35	0.00	241.35
g. Other expenditure	1972.17	2100.01	1828.71	7870.88	6840.18	8173.82	7190.40
TOTAL	33269.13	30624.56	27259.81	118535.73	89021.25	127122.03	90564.28
Profit from Operations before Other Income, Interest & Exceptional Items	2800.16	5255.85	3454.94	15303.83	13992.95	15676.89	14181.74
Other Income	177.00	0.00	0.00	1450.41	0.00	1450.41	0.00
Profit before Interest & Exceptional Items	2977.16	5255.85	3454.94	16754.24	13992.95	17127.30	14181.74
Interest	2128.49	2266.98	1944.11	8454.71	5587.18	8472.63	5589.70
Profit after Interest but before Exceptional Items	848.68	2988.87	1510.83	8299.54	8405.78	8654.67	8592.04
Extra ordinary item. (Reverse of Previous year Provision)	0.00	0.00	(72.80)	0.00	(306.77)	0.00	(306.77)
Profit (+)/ Loss (-) from Ordinary Activities before tax	848.68	2988.87	1583.63	8299.54	8712.55	8654.67	8898.81
Provision for taxation	261.26	595.68	335.85	1746.21	1796.54	1756.22	1798.20
Income Tax adjustment of Previous Year	0.71	0.00	(4.56)	(46.63)	(4.56)	(46.63)	(4.56)
Mat Credit Entitlement	(261.26)	(595.68)	(335.85)	(1746.21)	(1796.54)	(1746.21)	(1796.54)
Provision for deferred Tax	(987.60)	144.86	(1051.29)	(297.84)	(44.51)	(224.78)	(44.51)
Net Profit /Loss	1835.57	2844.01	2639.48	8644.01	8761.62	8916.08	8946.21
Provision for dividend on Equity Shares					342.23		342.23
Provision for Equity dividend Tax					56.84		56.84
Transfer to General reserve					438.08		438.08
Retained Profit	1835.57	2844.01	2639.48	8644.01	7924.47	8916.08	8109.06
Paid up Equity Share Capital	3794.55	3638.45	3,422.31	3,794.55	3422.31	3,794.55	3422.31
Reserve excluding revaluation reserves							
EPS Rs.							
Basic	5.12	8.06	8.96	24.10	29.76	25.48	30.38
Diluted	4.94	7.46	8.31	23.25	27.57	24.58	28.15
Public Shareholding							
Numbers of shares	19396344	19397124	19174724	19396344	19174724	19396344	19174724
% of Shareholding	51.12%	53.31%	56.03%	51.12%	56.03%	51.12%	56.03%
Promoters and Promoter group shareholding							
a) Pledged/Encumbered	Nil	Nil	Nil	Nil	Nil	Nil	Nil
b) Non-encumbered	Nil	Nil	Nil	Nil	Nil	Nil	Nil
Number of Shares	18549126	16987346	15048346	18549126	15048346	18549126	15048346
Percentage of shares (as a % of the total share capital of the company)	48.88%	46.69%	43.97%	48.88%	43.97%	48.88%	43.97%

For Ind-Swift Laboratories Ltd.

(Pardeep Verma)
 GM-Corporate Affairs & Company Secretary



Ind-Swift Laboratories Limited

(A Recognised Export House)

Regd. Office : S.C.O. 850, Shivalik Enclave, NAC, Manimajra, Chandigarh - 160 101
 Phones : ++ 91 - 172-2730503, 2730920, Fax ++ 91 - 172 - 2730504, 2736294
 E-mail : info@indswiftlabs.com Website : www.indswiftlabs.com



Audited Statements of Assets and Liabilities		(Rs. In Lacs)			
	As at	As at	As at	As at	
	31.03.2012	31.03.2011	31.03.2012	31.03.2011	
	STANDALONE		CONSOLIDATED		
I. EQUITY AND LIABILITIES					
(1) Shareholders' Funds					
a) Share Capital	3794.55	3422.31	3794.55	3422.31	
b) Reserves & Surplus	78308.61	53582.61	78384.03	53385.96	
c) Money received against share warrants	271.22	1002.38	271.22	1002.38	
(2) Non-current liabilities					
(a) Long-term borrowings	71104.29	59940.07	71104.29	59940.07	
(b) Deferred Tax Liabilities(Net)	4037.67	4335.51	4110.73	4335.51	
(c) Other Long term liabilities	2344.43	1706.00	2344.43	1706.00	
(3) Current Liabilities					
(a) Short term Borrowings	30183.08	21979.01	30183.08	21979.01	
(b) Trade Payable	23847.66	23264.41	25405.04	23533.75	
(c) Other current liabilities	4887.69	1642.16	4453.92	1820.35	
(d) Short term Provisions	1746.21	2195.61	1757.42	2197.26	
TOTAL	220525.41	173070.06	221808.71	173322.59	
II. ASSETS					
Non-Current Assets					
(1) (a) Fixed Assets					
(i) Tangible Assets	90203.33	55062.08	90203.33	55062.08	
(ii) Intangible Assets	13669.21	15083.36	13775.77	15108.44	
(iii) Capital work in Progress	29422.86	31529.62	29422.86	31529.62	
(iv) Assets held for disposal	223.36	223.36	223.36	223.36	
Accumulated depreciation	133518.76	101898.43	133625.33	101923.51	
Net Block	13229.46	15661.12	13229.46	15661.12	
	120289.31	86237.31	120395.87	86262.40	
(b) Non-Current investment	2723.03	2807.96	1709.56	1794.48	
(c) Long-term loans & advances	164.76	207.31	167.49	209.66	
(2) Current assets					
(a) Current investment	210.00	3010.00	210.00	3010.00	
(b) Inventories	49380.92	36554.71	49427.53	36554.71	
(c) Trade receivables	28180.28	28705.45	30378.41	29384.55	
(d) Cash and Cash equivalents	4622.96	4842.25	4692.32	5409.89	
(e) Short-term loans and advances	14954.15	10705.06	14957.22	10707.08	
(f) Foreign Currency Translation	0.00	0.00	(129.69)	(10.18)	
TOTAL	220525.41	173070.06	221808.71	173322.59	

Notes :-

- The Above results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective Meetings held on 30th May, 2012.
- During the quarter ended March, 2012, Company has allotted 15,61,000 equity shares upon conversion of Zero Coupon Warrants raising thereby a sum of Rs.965.87 lacs. The funds raised were utilized for Derabassi, Jammu and R&D Mohali facility expansion including capital advances and augmentation of NWC.
- A major fire occurred at M/s Dashmesh Medicare Private Limited, a loan licensee for ISLL for a main product, on continuous basis. Impact On ISLL could not be ascertained as the site is not released to Dashmesh yet.
- The Consolidated result includes the results of the US and Singapore Subsidiaries.
- Information on Investor Complaints for the quarter. Opening Balance NIL, Received Nil, Redressed Nil, Closing Balance NIL.
- The previous period figures have been re-grouped and re-arranged wherever necessary.
- The Company is exclusively in the Pharmaceutical business segment.

For Ind-Swift Laboratories Ltd.

For Ind-Swift Laboratories Ltd.

Place : Chandigarh
 Date : 30.05.2012

Sd/-
 (N.R. Munjal)
 Vice Chairman cum
 Managing Director

(Pardeep Verma)
 GM-Corporate Affairs & Company Secretary



Ind-Swift LABORATORIES Limited

(A Recognised Export House)

Regd. Office : S.C.O. 850, Shivalik Enclave, NAC, Manimajra, Chandigarh - 160 101
 Phones : ++ 91 - 172-2730503, 2730920, Fax + + 91 - 172 - 2730504, 2736294
 E-mail: info@indswiftlabs.com Website : www.indswiftlabs.com



TO ALL THE STOCK EXCHANGES

(Meeting of the Board of Directors of the Company held on 30th May, 2012 at 3.30 P.M.)

Statement of Appropriations (As per clause 20 of the Listing Agreement)

Name of Company:
For the year ended

IND-SWIFT LABORATORIES LTD.
1st April, 2011 - 31st March, 2012

(Rs. in lacs)

	2011-2012	2010-2011
1. Total Turnover and other Receipts	133839.56	103014.21
2. Gross Profit: (before deducting any of the following)	28074.38	24141.68
(a) Interest	8454.71	5587.18
(b) Depreciation	3986.09	3851.64
(c) Tax Liability	1746.21	1796.54
(d) Misc. Exp. W/O	-	-
3. Net Profit available for appropriation:	8644.01	8761.62
4. Provision for Investment Allowance Reserve	-	-
5. Net Profit/Loss	-	-
(a) Add/Less:		
B/fd. from Last year's Balance	24309.39	16384.92
(b) Other adjustment, if any, Add (Transfer from P&L Account)	8644.01	8761.62
Less: Transferred to		
i) General Reserve	NIL	438.08
ii) Deferred Tax Liability		
6. Dividend: (Including tax)	NIL	399.07
(a) Per Ordinary Shares of Rs. 10/- each.		
(b) Per Preference Share of Rs.100/- each.	NIL	NIL
7. Balance carried forward	32953.40	24309.39
8. Particulars of proposed Right/Bonus Shares/ Convertible Debenture Issue	NIL	NIL

1. Closure of Register of Members from : NOT DECIDED YET.

For IND-SWIFT LABORATORIES LTD.

(PARDEEP VERMA)
GM-CORPORATE AFFAIRS &
COMPANY SECRETARY